Abbott Laboratories ABT

Morningstar Rating
$91.25 +0.75 (0.83%)
View Full Chart

Company Report

Abbott Faces Near-Term Headwinds in Nutrition and Slower Long-Term Libre Growth

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely heavily on its ability to consistently introduce innovative products across divisions. On margins, the company has made much progress over the past 10 years but still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.

Price vs Fair Value

ABT is trading at a 678% premium.
Price
$90.50
Fair Value
$259.00
Uncertainty
Medium
1-Star Price
$432.18
5-Star Price
$94.20
Economic Moat
Ndztkcv
Capital Allocation
Kdnjgpqyz

Bulls Say, Bears Say

Bulls

Abbott has been investing in structural heart products, including the left atrial appendage closure and transcatheter mitral valve markets.

Bears

Edwards Lifesciences' Pascal device and its emerging portfolio of transcatheter mitral technologies are likely to put pressure on Abbott's MitraClip franchise over the longer term.

News

Trading Information

Previous Close Price
$90.50
Day Range
$90.1392.02
52-Week Range
$81.97139.06
Bid/Ask
$91.15 / $91.20
Shares Outstanding
1.74B
Market Cap
$158.94B
Volume/Avg
14M / 13M

Key Statistics

Price/Earnings (Normalized)
17.36
Price/Sales
3.50
Dividend Yield (Trailing)
2.67%
Dividend Yield (Forward)
2.76%
Total Yield
3.17%

Company Profile

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Value
Total Number of Employees
115,000

Competitors

Valuation

Metric
ABT
RHHBY
BSX
Price/Earnings (Normalized)
17.3615.8915.71
Price/Book Value
3.037.542.80
Price/Sales
3.504.263.53
Price/Cash Flow
15.4913.9715.09
Price/Earnings
ABT
RHHBY
BSX

Financial Strength

Metric
ABT
RHHBY
BSX
Quick Ratio
1.011.100.98
Current Ratio
1.391.381.90
Interest Coverage
15.5613.4611.40
Quick Ratio
ABT
RHHBY
BSX

Profitability

Metric
ABT
RHHBY
BSX
Return on Assets (Normalized)
10.23%15.77%10.92%
Return on Equity (Normalized)
17.96%49.73%19.65%
Return on Invested Capital (Normalized)
13.51%23.68%13.95%
Return on Assets
ABT
RHHBY
BSX

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Stryker Corp
SYK
PysvgkznYtdr$120B
Medtronic PLC
MDT
XmdfrmvBnmmwj$105B
Boston Scientific Corp
BSX
YxqqxcfkKxwjtv$73B
Edwards Lifesciences Corp
EW
ZrczcvsvmGzdmhr$50B
DexCom Inc
DXCM
GhdlmpnpkDvztf$30B
GE HealthCare Technologies Inc Common Stock
GEHC
GggmgjzvFhd$30B
Koninklijke Philips NV ADR
PHG
HnlyRrr$25B
Steris PLC
STE
NgssbkfCnghkp$21B
Zimmer Biomet Holdings Inc
ZBH
MfkvcmgbzTht$17B

Sponsor Center